HCA Healthcare (NYSE: HCA) Meets Q1 2026 Revenue Estimates as Profit Beats on Strong Care Demand

NYSE: HCA · April 24, 2026 · 3 min read

(NYSE: HCA) shares edged 0.57% higher to $474.03 on Friday despite an initial post-earnings dip, as investors parsed a first quarter that matched revenue expectations while adjusted earnings per share came in line with Wall Street's consensus. The results, confirmed via an 8-K filed with the SEC on April 24, 2026 under Item 2.02 (Results of Operations), reflected sustained demand for hospital and medical care services across HCA's network.

Q1 2026 At a Glance

• Revenue: $19.11 billion, up 4.3% year over year — in line with analyst estimates
• Adjusted EPS: $7.15, meeting Wall Street's consensus
• Net income: $1.62 billion for the quarter
• Trailing P/E: 16.7x | Forward P/E: 14.2x
• Net margin: 9.0% | Operating margin: 16.3% | Gross margin: 41.5%
• Revenue growth (YoY): 6.7% | Earnings growth (YoY): 44.5%
• 52-week range: $321.39 – $556.52

What Drove the Results

Strong and broad-based demand for medical care services was the primary engine behind HCA's first-quarter performance. Hospital operators have benefited from elevated patient volumes, and (NYSE: HCA) appears to have translated that demand into solid bottom-line results, with earnings growth of 44.5% year over year standing out as a particularly notable figure relative to the more modest revenue expansion.

The company's operating margin of 16.3% and gross margin of 41.5% suggest disciplined cost management alongside volume gains. A forward P/E of 14.2x — below the trailing multiple of 16.7x — implies that analysts expect continued earnings improvement, which is consistent with the strong year-over-year earnings growth already reported.

Wall Street View

Analyst sentiment toward (NYSE: HCA) remains broadly constructive. As of the April 2026 consensus, the stock carried 6 Strong Buy ratings, 12 Buy ratings, 12 Hold ratings, and just 1 Sell — a distribution that was unchanged from the prior month's tally. The stability in ratings suggests that analysts see the current setup as fairly balanced, with the bull case grounded in durable demand trends and the company's demonstrated earnings leverage.

Investor Takeaway

HCA Healthcare's Q1 2026 results present a picture of a large hospital operator executing steadily — revenue growth in line with expectations, earnings well ahead on a year-over-year basis, and margins that reflect operational discipline. The muted initial stock reaction, despite a solid report, may reflect the market's high bar given the stock's prior trading range. With analyst consensus stable and earnings growth running well ahead of revenue growth, the fundamental narrative for (NYSE: HCA) remains intact heading into the rest of 2026.